Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CD3 bispecific antibody true-killer combo

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 19, 2023 7:43pm

70 Views

Post# 35692088

RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

As already posted ... ONCY's synergy with bispecifics is even better than with anti-body drug conjugates (ADC) since ADCs are usually loaded with a chemotherapy agent while bispecifics are antibodies with two binding sites directed at two different antigens such as pelareorep + a CD3 surface antigen - which results in a more specific,, more effective and less toxic I/O agent than that of an ADC.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles